Should You Buy Tilray Stock Before July 15?

On July 15, the Drug Enforcement Administration will conclude its public hearing on the proposal to move cannabis from Schedule I to Schedule III. The hearing won't actually legalize marijuana, and it won't guarantee rescheduling. But it does represent the most significant federal review of cannabis policy in more than 50 years.Does this make Tilray Brands (NASDAQ: TLRY) a buy before then? Not necessarily. Let me explain.If cannabis moves to Schedule III, the biggest immediate beneficiaries are likely to be U.S. operators because the change would eliminate the punitive tax treatment imposed by IRS Section 280E. Tilray doesn't currently operate U.S. plant-touching cannabis businesses, so it wouldn't receive that same direct financial benefit.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool